复方斑蝥胶囊联合GP化疗治疗晚期非小细胞肺癌的效果

Abstract
Figure/Table
References (27)
Related Citation (15)

Download: PDF (610 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the efficacy of Compound Cantharidin Capsules combined with Gemcitabine and Cisplatin (GP) chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Eighty-two patients with advanced NSCLC admitted to Part Two in the First Hospital of Jilin University from January 2017 to December 2019 were selected, they were divided into control group (n = 41) and study group (n = 41) by random number table method. Control group was treated with GP chemotherapy regimen. Study group was treated with Compound Cantharidin Capsules on this basis. Clinical efficacy, immune function and tumor markers related indicators of two groups were compared，and the occurrence of adverse reactions of two groups was recorded. Results Total effective rate of study group was higher than that of control group (P < 0.05). After treatment, the levels of CD3+, CD4+, CD4+/CD8+ and NK cells in two groups were lower than those before treatment, and the level of CD8+ was higher than that before treatment, but the levels of CD3+, CD4+, CD4+/CD8+ and nature killer (NK) cells in study group were higher than those in control group, and the level of CD8+ was lower than that in control group (P < 0.05). After treatment, the levels of carcinoembryonic antigen, squamous cell carcinoma associated antigen and cytokeratin 19 fragment in two groups were lower than those before treatment, and those in study group were lower than those in control group (P < 0.05). The incidence rate of adverse reactions in study group was lower than that in control group (P < 0.05). Conclusion Compound Cantharidin Capsules combined with GP chemotherapy is effective in the treatment of advanced NSCLC. It can effectively alleviate immune suppression, improve the level of relevant tumor markers, and reduce the incidence of adverse reactions. It has high clinical value.

Key words： Compound Cantharidin Capsules Gemcitabine and Cisplatin chemotherapy Advanced non-small cell lung cancer Immune function Tumor markers

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHI Xu1 LIU Lijiao2 WANG Ye1 WANG Yan3

Cite this article:

CHI Xu1 LIU Lijiao2 WANG Ye1 WANG Yan3. Effect of Compound Cantharidin Capsules combined with GP chemotherapy in the treatment of advanced non-small cell lung cancer[J]. 中国医药导报, 2021, 18(5): 97-100,112.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2021/V18/I5/97

[1] 孔德琦，刘苓霜，姜怡，等.中医药干预Ⅲa期非小细胞肺癌根治术后无病生存期及预后相关因素分析[J].国际中医中药杂志，2019，41（1）：8-13.
[2] Mao Y，Yang D，He J，et al. Epidemiology of lung cancer [J]. Surg Oncol Clin N Am，2016，25（3）：439-445.
[3] Sacco PC，Maione P，Palazzolo G，et al. Treatment of advanced non-small cell lung cancer in the elderly [J]. Expert Rev Respir Med，2018，12（9）：783-792.
[4] Nagasaka M，Gadgeel SM. Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer [J]. Expert Rev Anticancer Ther，2018，18（1）：63-70.
[5] 高宇，林彦馨，杨跃辉.吉西他滨联合顺铂或卡铂治疗非小细胞肺癌的临床疗效及安全性分析[J].中国临床药理学杂志，2019，35（19）：2430-2434.
[6] Branden E，Hillerdal G，Kolbeck K，et al. Pemetrexed and gemcitabine versus carboplatin and gemcitabine in non-small cell lung cancer：a randomized noninferiority phase Ⅱ study in one center [J]. Oncologist，2015，20（4）：365.
[7] 赵士冲，谢长远，姚平刚.复方斑蝥胶囊对原发性肝癌介入治疗后细胞免疫功能的效果及机制[J].中华中医药学刊，2019，37（11）：2785-2787.
[8] 中华人民共和国卫生部.中国常见恶性肿瘤诊治规范[M].北京：北京医科大学、中国协和医科大学联合出版社，1991.
[9] 施世明，何健，黄艳，等.立体定向放疗治疗老年Ⅰ期肺癌的不良反应和疗效观察[J].复旦学报：医学版，2016， 43（2）：188-194.
[10] 黎鹏，肖志伟，林丽珠.鸦胆子油乳联合多西紫杉醇+顺铂方案治疗非小细胞肺癌临床评价[J].中国药业，2018， 27（15）：43-45.
[11] Bylicki O，Barazzutti H，Paleiron N，et al. First-line treatment of non-small-cell lung cancer （NSCLC） with immune checkpoint inhibitors [J]. Bio Drugs，2019，33（2）：159-171.
[12] 朱晓敏，王浩楠，郭春龙.多西他赛联合顺铂方案治疗晚期非小细胞肺癌的临床疗效评价[J].中国现代医生，2019，57（1）：65-67.
[13] 金元虹，潘炯伟.甲磺酸阿帕替尼片治疗晚期非小细胞肺癌的临床效果分析[J].中国现代医生，2019，57（10）：112-115.
[14] Ma D，Wang J，Hao X，et al. Gemcitabine combined with cisplatin as adjuvant chemotherapy for non-small cell lung cancer：a retrospective analysis [J]. Thorac Cancer，2017，8（5）：482-488.
[15] 张亚平.DP化疗方案与GP化疗方案治疗晚期非小细胞肺癌患者108例临床对比研究[J].现代诊断与治疗，2018，29（13）：2093-2095.
[16] 许珍珍.中医护理模式对中医保守治疗肺癌患者睡眠质量与生活质量的改善效果研究[J].湖北中医药大学学报，2018，20（1）：103-105.
[17] 封佳莉，李和根，周晓辉，等.中医药干预874例晚期非小细胞肺癌的生存分析[J].安徽中医药大学学报，2019， 38（6）：10-15.
[18] 宋展，周丽荣，王晓晟，等.复方斑蝥胶囊联合奥沙利铂治疗非小细胞肺癌的疗效观察[J].现代药物与临床，2019，34（5）：1525-1528.
[19] Dogan E，Ucar M，Sakalar T，et al. Biweekly cisplatin and gemcitabine with two different doses in non small cell lung cancer patients：a retrospective singlecenter experience [J]. J Buon，2018，23（4）：1070-1076.
[20] 朱振宇.吉西他滨和顺铂联合化疗治疗晚期非小细胞肺癌的临床疗效观察[J].中国医药指南，2017，15（3）：30.
[21] 赵骏.复方斑蝥胶囊与吉非替尼联合对非小细胞肺癌患者疗效评价[J].中成药，2019，41（4）：959-962.
[22] 洪桂花，陈思环，黄珊.复方斑蝥胶囊对原发性肝癌患者免疫功能及临床疗效的影响[J].世界中西医结合杂志，2020，15（2）：365-368，373.
[23] 孙洪帅，朱华，高海燕，等.肿瘤标志物SCC-Ag、CEA、CYFRA21-1和D-二聚体联合检测对非小细胞肺癌的早期诊断价值[J].吉林大学学报：医学版，2018，44（5）：1020-1024.
[24] 黄建清，何爱国，李亮，等.复方斑蝥胶囊联合GP方案治疗中晚期肺鳞癌的临床效果[J].实用癌症杂志，2019， 34（6）：968-970.
[25] 王丽发.复方斑蝥胶囊联合化疗治疗弥漫大B细胞淋巴瘤的临床研究[J].癌症进展，2018，16（5）：647-649， 662.
[26] 张栓宝，严宁娟，张燕平.复方斑蝥胶囊对非小细胞肺癌患者围术期血清炎症因子及免疫功能的影响[J].陕西中医，2019，40（7）：890-892.
[27] 刘霞，宋立业，宋琪，等.复方斑蝥胶囊对胃癌Th17/Treg细胞失衡及生命质量的影响[J].世界中医药，2018， 13（8）：1891-1894，1898.